Editas Medicine, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a EDIT research report →
About the company
Editas Medicine, Inc. , a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology.
- CEO
- Gilmore O'Neill
- IPO
- 2016
- Employees
- 87
- HQ
- Cambridge, MA, US
Price Chart
Get TickerSpark's AI analysis on EDIT
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
- Market Cap
- $291.74M
- P/E
- -2.43
- P/S
- 7.54
- P/B
- 66.17
- EV/EBITDA
- -2.40
- Div Yield
- 0.00%
- Gross Margin
- 5.83%
- Op Margin
- -297.50%
- Net Margin
- -281.59%
- ROE
- -677.39%
- ROIC
- -93.01%
- Revenue
- $40.52M · 25.39%
- Net Income
- $-160,060,000 · 32.49%
- EPS
- $-1.80 · 37.50%
- Op Income
- $-99,336,000
- FCF YoY
- 24.31%
- 52W High
- $4.54
- 52W Low
- $1.66
- 50D MA
- $2.96
- 200D MA
- $2.69
- Beta
- 2.10
- Avg Volume
- 2.51M
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 17, 26 | Connaughton Bernadette | other | 51,700 |
| Jun 17, 26 | Hopfield Jessica | other | 51,700 |
| Jun 17, 26 | Hirsch Andrew | other | 51,700 |
| Jun 17, 26 | Scadden David | other | 51,700 |
| Jun 17, 26 | Levy Elliott M. | other | 51,700 |
| Jun 3, 26 | Parison Amy | sell | 464 |
| Jun 3, 26 | O'Neill Gilmore Neil | sell | 15,380 |
| Jun 3, 26 | Burkly Linda | sell | 731 |
| Mar 12, 26 | O'Neill Gilmore Neil | other | 1,015,200 |
| Mar 12, 26 | Parison Amy | other | 292,856 |
Our EDIT coverage
Recent articles, reports, and earnings notes.
AI Biotech Stocks That Show Real Revenue: 7 Picks Worth Watching
These seven AI biotech stocks span diagnostics, software, platform discovery, and commercial therapeutics, ranked by investment quality for June 2026.
Top Gene Editing Stocks: Our 7 Picks for 2026
These seven gene editing stocks span CRISPR leaders, base and prime editors, and in vivo delivery plays, with CRISPR Therapeutics ranking highest on overall investment quality.
Want a deeper read on EDIT?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Similar companies
Peers in the same neighborhood.